NCT05496569 2025-11-21
TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Terminated
Clinical Trials
6 trialsNCT05580588 2025-06-13
Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas
Shanghai Pharma Biotherapeutics USA Inc.
Phase 2 Terminated
NCT04996004 2024-12-11
TTI-621-03
Pfizer
Phase 2 Terminated
NCT05116683 2023-12-06
ATX-101
Columbia University
Phase 2 Terminated
NCT01876043 2021-01-25
APLIPO
Institut Bergonié
Phase 2 Terminated
NCT02609984 2020-07-07
IMDZ-C232
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Terminated